Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View

Dr. Rishi Wadhera

General Cardiology · BIDMC

View

Dr. Robert Harrington

General Cardiology · WCM

View

Dr. Mike Gaziano

General Cardiology · BWH

View

Dr. Tyler Gluckman

General Cardiology · Providence

View

Dr. Cayla Pichan

General Cardiology · UT Southwestern

View

Dr. Sanjiv Kaul

General Cardiology · OHSU

View

Dr. Emily Lau

General Cardiology · MGH

View

Dr. Sarah Ashley

General Cardiology · Emory University Hospital

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand?

    May 19, 2025DOI: 10.1161/circulationaha.125.074100Journal ArticleAHA

    Written by: Siddharth M PatelRobert P GiuglianoChristian T Ruff

    Find these authors on Roon

    CR
    Dr. Christian Ruff
    General Cardiology · PHS

    Introduction

    Factor XI (FXI) inhibitors are an emerging class of anticoagulants being investigated to reduce the risk of thromboembolism but with a lower risk of bleeding relative to current anticoagulants - a hypothesis supported by epidemiologic and genetic data from patients with congenital FXI deficiency. Prevention of thromboembolism in atrial fibrillation (AF) represents the largest and one of the most promising indications for FXI inhibitors given the high risk for both ischemic and bleeding events in this patient population. Phase 2 dose-ranging studies have been conducted across several FXI inhibitors in development, and the collective data across these studies suggest much lower rates of bleeding compared with currently approved anticoagulants. These smaller studies were not designed to assess efficacy. However, a phase 3 trial of an activated FXI (FXIa) inhibitor in AF was terminated early because of inferior efficacy with respect to prevention of stroke/systemic embolism (SE) compared with a direct oral anticoagulant (DOAC).1 Several other phase 3 trials of different FXI inhibitors in AF are ongoing.

    Recent and Ongoing FXI Inhibitor Trials in AF

    AZALEA-TIMI 71 was a phase 2b study designed to assess the bleeding profile of two doses of abelacimab, a monoclonal antibody that binds inactive FXI thereby preventing generation of FXIa, versus rivaroxaban in 1,287 patients with AF at moderate-to-high risk for stroke.2 The trial was stopped early on recommendation of the independent data monitoring committee (IDMC) due to a greater than anticipated reduction in major or clinically relevant non-major bleeding with abelacimab vs. rivaroxaban (HR 0.38 [0.24–0.60] and 0.31 [0.19–0.51] for abelacimab 150 and 90 mg vs. rivaroxaban respectively). The trial was not powered to assess efficacy with a total of only 28 stroke/SE events; no significant differences were observed across treatment arms though events were numerically greater in the abelacimab arms (10 and 11 vs. 7 events for abelacimab 150 and 90 mg vs. rivaroxaban; HR 1.47 [0.56–3.85] and 1.65 [0.64–4.25] respectively). OCEANIC-AF was a phase 3 study designed to examine the efficacy and safety of asundexian, a small molecule FXIa inhibitor, relative to apixaban in 16,436 patients with AF.1 OCEANIC-AF was terminated early on recommendation of their IDMC due to inferiority of asundexian vs. apixaban for prevention of stroke/SE (98 vs. 26 events, HR 3.79 [2.46–5.83]). ISTH major bleeding was lower with asundexian relative to apixaban (HR 0.32 [0.18–0.55]). The phase 3 LIBREXIA-AF trial studying milvexian, another small molecule FXIa inhibitor, vs. apixaban for stroke prevention in AF is ongoing.

    Differences in Potency

    For anticoagulant drug development, smaller phase 2 studies in patients undergoing knee arthroplasty at high risk for venous thromboembolism (VTE) are traditionally conducted to demonstrate proof-of-concept that the anticoagulant reduces ischemic events and to guide dose selection for larger phase 3 stroke prevention in AF trials. Such studies were performed for all DOACs currently approved for AF. For the FXI inhibitors, both milvexian and abelacimab at the doses being studied in ongoing phase 3 outcomes trials, significantly reduced VTE compared with standard-of-care enoxaparin prophylaxis in patients after knee arthroplasty, without a significant increase in bleeding.3,4 For asundexian, however, efficacy was not assessed in knee arthroplasty but guided by a novel proprietary pharmacodynamic assay. Importantly, no standardized assay exists for assessment of FXIa activity and the relationship between the magnitude of reduction in FXIa activity and clinical outcomes remains uncertain. Moreover, while difficult to directly compare potency across agents owing to differences in mechanism of action and assays used, data raise the possibility that the asundexian 50 mg dose studied in OCEANIC-AF may have had meaningfully lower inhibition of the FXI pathway compared with abelacimab or milvexian at the doses being studied in phase 3 trials.5

    Differences in Mechanism of Action

    Differences in the mechanism of action across the class may also have implications for efficacy. While all DOACs inhibit the activated form of factors X or II, there exists mechanistic heterogeneity among the FXI pathway inhibitors. Some agents target inactive FXI thereby preventing generation of FXIa, whereas others target FXIa thus inhibiting FXIa activity, and a subset inhibit both FXIa generation and FXIa activity. Whether downstream inhibition of FXIa activity achieves similar efficacy for prevention of thromboembolism as upstream inhibition of FXIa generation remains uncertain. Mechanisms bypassing FXI for downstream FIXa generation may also play a role. There also exist important differences in both drug modality and delivery among agents in development. For example, abelacimab is a monoclonal antibody which is injected subcutaneously monthly, whereas both milvexian and asundexian are small molecule inhibitors which are administered orally – with dosing frequency ranging from daily to twice daily. Other agents include anti-sense oligonucleotides or small interfering RNAs which inhibit hepatic synthesis of FXI, typically dosed monthly or even less frequently. Thus, the results of ongoing phase 3 trials are necessary to determine whether there exists differential efficacy dependent on the mechanism of FXI inhibition, drug modality, and dosing frequency.

    Expected vs. Observed Rates of Stroke/SE

    While efficacy for prevention of VTE has been predictive of efficacy for prevention of arterial thromboembolism as observed for the DOACs, there exists the possibility that such generalizability may not apply with FXI/FXIa inhibition as with FXa or FIIa inhibition. For populations with AF and a similar thromboembolic risk profile to that in AZALEA-TIMI 71 and OCEANIC-AF (mean CHA2DS2VASc of 4.8 and 4.3 respectively), the rate of stroke/SE would be expected to be on the order of ~6–7 per 100 patient-years or greater for those not treated with anticoagulation based on historical epidemiologic cohorts, and ~1–2 per 100 patient-years in those treated with anticoagulation as observed in the pivotal phase 3 trials of DOAC vs. warfarin in AF. By comparison, the rates of stroke/SE for asundexian 50 mg and abelacimab 150 mg, the dose being carried forward for phase 3 outcomes trials, were numerically lower (3.85 and 1.21 per 100 patient-years, respectively) than would be expected among patients with AF of similar thromboembolic risk not treated with anticoagulation.
    However, it is also important to acknowledge that the expected thromboembolic rates extrapolated from historical non-anticoagulated populations may differ in the contemporary era owing to several secular trends including more aggressive risk factor modification ranging from smoking cessation, hypertension control and lipid lowering, and potentially earlier clinical recognition of AF in those with lower AF burden. As well, other factors may contribute to differences in thromboembolic risk across trials which may not be fully captured by traditional metrics such as the CHA2DS2VASc. Thus, such inter-trial comparisons should be interpreted with extreme caution and only randomized head-to-head comparisons of FXI pathway inhibitors versus DOAC, as in the ongoing LIBREXIA-AF study, and versus placebo as in the ongoing LILAC-TIMI 76 study, can definitively characterize the balance of efficacy and safety of FXI inhibitors in AF.

    Summary

    For the FXI/FXIa inhibitors, several factors unique to each of the individual agents, including mechanism of action, drug modality, dosing frequency and potency, may have important implications for differences in efficacy and safety. Thus, it is unlikely that the results observed with one FXI inhibitor can be generalized to the entire class of therapies. Whether FXI inhibitors will achieve the high degree of efficacy as demonstrated by the DOACs or vitamin-K-antagonists for prevention of thromboembolic events in patients with AF remains to be seen.
    CRDr. Christian Ruff

    Dr. Christian Ruff

    Cardiology · General Non-Invasive Cardiology
    Mass General Brigham
    christianruff